<DOC>
	<DOCNO>NCT01967966</DOCNO>
	<brief_summary>This 2-arm , open-label , non-randomized study investigate absolute bioavailability , pharmacokinetics , mass balance , rout elimination GDC-0032 well safety healthy volunteer . Patients receive either single oral dose GDC-0032 follow 14C-labeled IV dose GDC-0032 single oral dose 14C-labelled GDC-0032 .</brief_summary>
	<brief_title>A Bioavailability Pharmacokinetic Study GDC-0032 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive ; Healthy , judge physician medical history , 12lead ECG , vital sign , clinical laboratory evaluation ; Agree use effective contraceptive method define protocol ; Negative hepatitis panel HIV screen ; Sufficient bowel movement ( minimum 1 per day ) . History clinical manifestation : major medical disorder ; food/drug/substance allergy ; History stomach intestinal surgery resection except appendectomy and/or hernia repair ; History alcoholism drug addiction within 1 year prior drug administration ; Tobacco nicotine use within 6 month prior study start ; Chronic use gastric acid inhibitor within 6 month study start use gastric acid inhibitor and/or antacid within 1 month prior drug administration ; Evidence malabsorption syndrome condition interfere gastrointestinal absorption ; Inability unwillingness swallow capsule ; Participation drug study drug administer within 30 day prior study start ; Participation one radiolabeled drug study within 12 month precede drug administration . The previous radiolabeled study drug must receive 6 month prior study , total exposure study previous study less 5000 mrem whole body annual exposure ; Exposure significant radiation within 12 month prior study start .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>